Latest Insider Transactions at Neurocrine Biosciences Inc (NBIX)
This section provides a real-time view of insider transactions for Neurocrine Biosciences Inc (NBIX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of NEUROCRINE BIOSCIENCES INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of NEUROCRINE BIOSCIENCES INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 08
2024
|
David W. Boyer Chief Corp. Affairs Officer |
SELL
Open market or private sale
|
Direct |
1,328
-11.31%
|
$179,280
$135.49 P/Share
|
|
Feb 08
2024
|
Julie Cooke Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
1,329
-3.64%
|
$179,415
$135.5 P/Share
|
|
Feb 08
2024
|
Darin Lippoldt Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
911
-2.3%
|
$122,074
$134.24 P/Share
|
|
Feb 08
2024
|
Eiry Roberts Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
980
-4.14%
|
$131,320
$134.21 P/Share
|
|
Feb 08
2024
|
Kevin Charles Gorman Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,274
-0.45%
|
$304,716
$134.15 P/Share
|
|
Feb 08
2024
|
Eric Benevich Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
980
-2.41%
|
$131,320
$134.19 P/Share
|
|
Feb 08
2024
|
Kyle Gano Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
980
-0.73%
|
$131,320
$134.2 P/Share
|
|
Feb 08
2024
|
Matt Abernethy Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
980
-3.13%
|
$131,320
$134.21 P/Share
|
|
Feb 06
2024
|
David W. Boyer Chief Corp. Affairs Officer |
SELL
Open market or private sale
|
Direct |
456
-4.36%
|
$64,296
$141.96 P/Share
|
|
Feb 06
2024
|
Julie Cooke Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
1,215
-3.34%
|
$172,530
$142.07 P/Share
|
|
Feb 06
2024
|
Darin Lippoldt Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,041
-2.67%
|
$147,822
$142.17 P/Share
|
|
Feb 06
2024
|
Eiry Roberts Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,121
-4.88%
|
$159,182
$142.24 P/Share
|
|
Feb 06
2024
|
Kevin Charles Gorman Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
3,040
-0.6%
|
$431,680
$142.18 P/Share
|
|
Feb 06
2024
|
Eric Benevich Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,280
-3.2%
|
$181,760
$142.12 P/Share
|
|
Feb 06
2024
|
Kyle Gano Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,600
-1.19%
|
$227,200
$142.2 P/Share
|
|
Feb 06
2024
|
Matt Abernethy Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,280
-4.17%
|
$181,760
$142.19 P/Share
|
|
Feb 01
2024
|
Ingrid Delaet Chief Regulatory Officer |
SELL
Open market or private sale
|
Direct |
623
-8.32%
|
$86,597
$139.77 P/Share
|
|
Jan 31
2024
|
Darin Lippoldt Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,250
-3.27%
|
$175,000
$140.65 P/Share
|
|
Jan 31
2024
|
Jude Onyia Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
126
-1.05%
|
$17,766
$141.94 P/Share
|
|
Jan 31
2024
|
Eiry Roberts Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,457
-6.54%
|
$203,980
$140.79 P/Share
|
|
Jan 31
2024
|
Kevin Charles Gorman Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,707
-0.54%
|
$378,980
$140.69 P/Share
|
|
Jan 31
2024
|
Kyle Gano Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,541
-1.16%
|
$215,740
$140.7 P/Share
|
|
Jan 31
2024
|
Julie Cooke Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
1,740
-4.69%
|
$245,340
$141.32 P/Share
|
|
Jan 31
2024
|
Ingrid Delaet Chief Regulatory Officer |
SELL
Open market or private sale
|
Direct |
422
-6.27%
|
$59,502
$141.94 P/Share
|
|
Jan 31
2024
|
Eric Benevich Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,207
-3.11%
|
$168,980
$140.78 P/Share
|
|
Jan 31
2024
|
David W. Boyer Chief Corp. Affairs Officer |
SELL
Open market or private sale
|
Direct |
2,096
-16.32%
|
$293,440
$140.79 P/Share
|
|
Jan 31
2024
|
Matt Abernethy Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,283
-4.34%
|
$179,620
$140.72 P/Share
|
|
Jan 22
2024
|
Darin Lippoldt Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
10,000
-21.8%
|
$1,390,000
$139.86 P/Share
|
|
Jan 22
2024
|
Darin Lippoldt Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+17.89%
|
$790,000
$79.02 P/Share
|
|
Jan 09
2024
|
Kevin Charles Gorman Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
62,023
-11.04%
|
$8,311,082
$134.01 P/Share
|
|
Jan 09
2024
|
Kevin Charles Gorman Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
62,023
+9.94%
|
$1,178,437
$19.59 P/Share
|
|
Jan 08
2024
|
Kevin Charles Gorman Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
105,835
-17.48%
|
$13,970,220
$132.44 P/Share
|
|
Jan 08
2024
|
Kevin Charles Gorman Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
105,835
+14.88%
|
$2,010,865
$19.59 P/Share
|
|
Jan 02
2024
|
Kyle Gano Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
75,000
-19.54%
|
$9,825,000
$131.46 P/Share
|
|
Jan 02
2024
|
Kyle Gano Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
75,000
+15.0%
|
$1,425,000
$19.59 P/Share
|
|
Jan 02
2024
|
William H Rastetter Director |
SELL
Open market or private sale
|
Direct |
11,044
-17.59%
|
$1,446,764
$131.47 P/Share
|
|
Jan 02
2024
|
William H Rastetter Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+24.16%
|
$240,000
$12.98 P/Share
|
|
Dec 22
2023
|
Eiry Roberts Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
10,000
-33.87%
|
$1,260,000
$126.74 P/Share
|
|
Dec 22
2023
|
Gary A Lyons Director |
SELL
Open market or private sale
|
Direct |
10,000
-4.91%
|
$1,300,000
$130.04 P/Share
|
|
Dec 22
2023
|
Julie Cooke Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
24,000
-40.73%
|
$3,072,000
$128.39 P/Share
|
|
Dec 22
2023
|
Julie Cooke Chief Human Resources Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
24,000
+28.88%
|
$1,704,000
$71.44 P/Share
|
|
Dec 12
2023
|
Eiry Roberts Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
13,925
-19.08%
|
$1,671,000
$120.31 P/Share
|
|
Dec 12
2023
|
Eiry Roberts Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,925
+16.03%
|
$1,127,925
$81.05 P/Share
|
|
Dec 08
2023
|
Eiry Roberts Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
300
-0.51%
|
$36,000
$120.08 P/Share
|
|
Dec 08
2023
|
Eiry Roberts Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
300
+0.5%
|
$24,300
$81.05 P/Share
|
|
Dec 07
2023
|
Eiry Roberts Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
77,379
-36.95%
|
$9,285,480
$120.37 P/Share
|
|
Dec 07
2023
|
Eiry Roberts Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
77,379
+26.5%
|
$6,035,562
$78.92 P/Share
|
|
Dec 06
2023
|
Eiry Roberts Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
8,396
-22.14%
|
$1,007,520
$120.03 P/Share
|
|
Dec 06
2023
|
Eiry Roberts Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,396
+18.13%
|
$646,492
$77.81 P/Share
|
|
Dec 06
2023
|
Darin Lippoldt Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
20,830
-36.73%
|
$2,478,770
$119.86 P/Share
|